Regeneron Pharma falls after quarterly results miss

Drugmaker Regeneron Pharmaceuticals' REGN.O shares fall 7% to $568 premarket

Co posts Q1 adj. profit of $8.22/shr, missing analysts' estimates of $8.82, according to data compiled by LSEG

Reports Q1 revenues of $3.03 billion vs estimates of $3.27 billion

Says global sales for its blockbuster lung disease drug, Dupixent, rose 19% in Q1 to $3.67 billion

However, U.S. sales of dry eye disease drugs Eylea and Eylea HD fell 26% to $1.4 billion

"While we anticipated this may be a more messy quarter for Eylea due to ongoing funding concerns for patient assistance charities, other factors further exacerbated this dynamic" - Brokerage BMO Capital Markets

As of last close, REGN has fallen 14.2% YTD